Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NRIX stock hub

Nurix Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NRIXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.7B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

NRIX

In the news

Latest news · NRIX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-61.4

P25 -105.6P50 -46.5P75 -3.1

ROIC-37.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NRIX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

204

Groups with data

Currency

USD

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001549595
Company name	Nurix Therapeutics, Inc.
Country	United States
Country code	US
Cusip	67080M103
Employees	317
Employees Change	31%
Employees Change Percent	10.84
Enterprise value	$1.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-07-24
Isin	US67080M1036
Last refreshed	2026-05-10
Market cap	$1.7B
Market cap category	Small-Cap
Price	$16.52
Price currency	USD
Rev Per Employee	226,432.18x
Sector	Healthcare
Sic	2834
Symbol	NRIX
Website	https://www.nurixtx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-17.29%
EV Sales Forward	17.44x
EV/Sales	17.08x
FCF yield	-15.91%
P/B ratio	3.55x
P/S ratio	23.8x
PS Forward	24.3x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-259.6M
Net Income	$-295.3M
Net Income Growth Years	0%
Pretax Margin	-410.31%
Profit Per Employee	$-931,483
ROA	-31.5
Roa5y	-24
ROCE	-57.97
ROE	-61.4
Roe5y	-50.57
ROIC	-37.64

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	77.7%
Cagr3y	19.5%
Cagr5y	-9.32%
EPS Growth Years	0
Revenue Growth	27.23x
Revenue Growth Q	-66.12x
Revenue Growth Years	1x
Revenue Growth3 Y	19.85x
Revenue Growth5 Y	29.16x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.11
Assets	$636.1M
Cash	$540.7M
Current Assets	$554.4M
Current Liabilities	$92.2M
Debt	$58.7M
Debt Equity	$0.12
Equity	$480.9M
Liabilities	$155.2M
Long Term Assets	$81.7M
Long Term Liabilities	$63M
Net Cash	$482.1M
Net Cash By Market Cap	$28.22
Net Cash Growth	-7.83%
Net Debt Equity	$-1
Tangible Book Value	$480.9M
Tangible Book Value Per Share	$4.65
WACC	14.09

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.01
Net Working Capital	$-75.3M
Quick ratio	5.89
Working Capital	$462.2M
Working Capital Turnover	$0.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-25.59%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	77.63%
200-day SMA	14.23
3Y total return	70.66%
50-day SMA	15.94
50-day SMA vs 200-day SMA	50over200
5Y total return	-38.68%
All Time High	52.38
All Time High Change	-68.46%
All Time High Date	2020-12-14
All Time Low	4.22
All Time Low Change	291.47%
All Time Low Date	2023-10-26
ATR	0.82
Beta	1.88
Beta1y	0.79
Beta2y	1.49
Ch YTD	-12.92
High	16.62
High52	22.5
High52 Date	2025-12-08
High52ch	-26.58%
Low	16.23
Low52	8.2
Low52 Date	2025-09-23
Low52ch	101.59%
Ma50ch	3.63%
Premarket Change Percent	1.35
Premarket Price	$16.5
Premarket Volume	1,936
Price vs 200-day SMA	16.11%
RSI	50.93
RSI Monthly	52.86
RSI Weekly	54.03
Sharpe ratio	1.17x
Sortino ratio	2.11
Total Return	-25.59%
Tr YTD	-12.92
Tr1m	1.04%
Tr1w	-1.73%
Tr3m	-1.96%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	12
Analyst Count Top	4
Analyst Price Target Top	$31.25
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.76
Earnings Revenue Estimate	14,387,520x
Earnings Revenue Estimate Growth	-22.03x
Operating Income	$-315.3M
Operating margin	-439.3
Price target	$30.5
Price Target Change	$84.63
Price Target Change Top	$89.17

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	88,208,738%
Float Percent	85.3%
Shares Insiders	0.51%
Shares Institutions	95.14%
Shares Out	103,405,813
Shares Qo Q	15.76%
Shares Yo Y	25.59%
Short Float	21.77%
Short Ratio	12.86
Short Shares	18.57

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-310.5M
Average Volume	911,133x
Bv Per Share	4.65
CAPEX	$-11.6M
Ch1m	1.04
Ch1w	-1.73
Ch1y	77.63
Ch3m	-1.96
Ch3y	70.66
Ch5y	-38.68
Ch6m	34.2
Change	1.47%
Change From Open	1.41
Close	16.28
Days Gap	0.06
Depreciation Amortization	7,986,000
Dollar Volume	21,374,187.2
Earnings Date	2026-04-08
Earnings Time	bmo
EBIT	$-315.3M
EBITDA	$-307.3M
EPS	$-3.17
F Score	1
FCF	$-271.9M
FCF EV Yield	-22.17x
FCF Per Share	$-2.63
Financing CF	257,144,000
Fiscal Year End	November
Founded	2,009
Income Tax	$760,000
Investing CF	-1,506,000
Ipr	-13.05
Iprfo	-8.53
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-08
Last Report Date	2026-02-28
Last Split Type	Never
Last10k Filing Date	2026-01-28
Ma150	15.71
Ma150ch	5.14%
Ma20	16.68
Ma20ch	-0.97%
Net CF	-4,654,000
Next Earnings Date	2026-07-08
Open	16.29
Optionable	Yes
Position In Range	74.36
Post Close	16.52
Postmarket Change Percent	0.48
Postmarket Price	$16.6
Ppne	73,354,000
Pre Close	16.28
Price Date	2026-05-08
Ptbv Ratio	3.55
Relative Volume	1.42x
Revenue	71,779,000x
SBC By Revenue	53.84x
Share Based Comp	38,647,000
Tax By Revenue	1.06x
Tr6m	34.2%
Us State	California
Volume	1,293,837
Z Score	1.31

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NRIX pay a dividend?

Capital-return profile for this ticker.

Performance

NRIX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NRIX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+95.1%

Float: +85.3% of shares outstanding

Insider ownership

+0.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

NRIX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

50.9

Neutral momentum band

Price vs 200-day MA

+16.1%

50/200-day relationship not available

Beta (5Y)

1.88

More volatile than the market

Sharpe ratio

1.17

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NRIX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NRIX stock rating?

Nurix Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NRIX analysis?

The full report lives at /stocks/NRIX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NRIX?

The latest report frames NRIX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NRIX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.